Table 2.

Number of irAEs grouped by 18 tissue or organ disorders for FDA-approved ICIs

	Cemiplimab	Nivolumab	Pembrolizumab	Atezolizumab	Avelumab	Durvalumab	Ipilimumab
	Number/ratio	Number/ ratio	Number/ ratio	Number/ ratio	Number/ratio	Number/ ratio	Number/ratio
BL	49/0.078	4,336/0.051	2,975/0.057	2,070/0.097	163/0.064	604/0.075	438/0.054
CD	35/0.056	3,947/0.046	2,117/0.040	1,074/0.050	151/0.060	435/0.054	561/0.069
ELD	1/0.002	382/0.004	177/0.003	93/0.004	7/0.003	29/0.004	18/0.002
EnD	25/0.040	4,346/0.051	2,234/0.043	848/0.040	124/0.049	289/0.036	289/0.036
ED	8/0.013	1,664/0.019	919/0.018	269/0.013	27/0.011	108/0.013	78/0.010
GD	62/0.099	11,231/0.131	6,505/0.124	3,093/0.145	357/0.141	939/0.117	1,233/0.152
HD	50/0.080	4,666/0.055	3,009/0.057	1,405/0.066	133/0.053	463/0.058	553/0.068
ID	33/0.053	1,539/0.018	1,151/0.022	366/0.017	60/0.024	84/0.010	98/0.012
MnD	39/0.062	6,095/0.071	3,012/0.058	1,494/0.070	173/0.068	342/0.043	490/0.060
McD	30/0.048	5,544/0.065	3,280/0.063	1,029/0.048	145/0.057	418/0.052	335/0.041
NMU	36/0.057	10,113/0.118	6,764/0.129	1,121/0.053	153/0.060	1,008/0.126	1,781/0.220
NsD	69/0.110	7,168/0.084	4,278/0.082	1,990/0.093	243/0.096	627/0.078	559/0.069
PD	16/0.025	1,836/0.021	1,136/0.022	381/0.018	45/0.018	148/0.018	159/0.020
RuD	31/0.49	3,827/0.045	2,661/0.051	1,261/0.059	162/0.064	259/0.032	382/0.047
RB	3/0.005	259/0.003	205/0.004	95/0.004	6/0.002	20/0.002	14/0.002
RTM	73/0.116	9,317/0.109	5,755/0.110	2,429/0.114	277/0.110	1,526/0.190	849/0.105
SSD	40/0.064	6,631/0.078	4,414/0.084	1,362/0.064	168/0.066	439/0.055	1/0.000
VD	28/0.045	2,550/0.030	1,743/0.033	918/0.043	135/0.053	283/0.035	271/0.033
Total number cases	628	85,451	52,335	21,298	2,529	8,021	8,109